Effects of dopamine, NMDA, opiate, and serotonin-related agents on acute methamphetamine-induced self-injurious behavior in mice

Pharmacology Biochemistry and Behavior

Volumn 66, Issue 3, 2000, Pages 579-583

  Shishido, Toshiaki ^a   Watanabe, Yoshinori ^a   Kato, Kozo ^a   Horikoshi, Ryu ^a   Niwa, Shin Ichi ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

D2 receptor; Dopamine D1 receptor; Methamphetamine; N Methyl D aspartate receptor; Opiate receptor serotonin; Self injurious behavior

Indexed keywords

5 HYDROXYTRYPTOPHAN; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DIZOCILPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; GLUTAMATE RECEPTOR ANTAGONIST; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALOXONE; OPIATE ANTAGONIST; OPIATE RECEPTOR; SEROTONIN; SULPIRIDE;

ANIMAL EXPERIMENT; ARTICLE; AUTOMUTILATION; BEHAVIOR DISORDER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HUMAN; LOCOMOTION; MALE; MOUSE; NEUROTRANSMISSION; PRIORITY JOURNAL; STEREOTYPY;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; 5-HYDROXYTRYPTOPHAN; ANIMALS; DIZOCILPINE MALEATE; DOPAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; MALE; METHAMPHETAMINE; MICE; MICE, INBRED BALB C; MOTOR ACTIVITY; N-METHYLASPARTATE; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; RECEPTORS, N-METHYL-D-ASPARTATE; SELF-INJURIOUS BEHAVIOR; SEROTONIN AGENTS; SULPIRIDE;

EID: 0033945821     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(00)00219-7     Document Type: Article

References (34)

1. Balcells-Olivero M., Vezina P. Effects of naltrexone on amphetamine-induced locomotion and rearing. Acute and repeated injections Psychopharmacology (Berlin). 131:1997;230-238.
2. Berretta S., Robertson H.A., Graybiel A.M. Dopamine and glutamate agonists stimulate neuron-specific expression of Fos-like protein in the striatum. J. Neurophysiol. 68:1992;767-777.
3. Breese G.R., Baumeister A.A., McCown T.J., Emerick S.G., Frye G.D., Crotty K., Mueller R.A. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonist. Relevance to neurological symptoms in clinical syndromes with reduced brain dopamine J. Pharmacol. Exp. Ther. 231:1984;343-354.
4. Breese G.R., Baumeister A.A., Celeste napier T., Fray G.D., Mueller R.A. Evidence that D-1 dopamine receptors contribute to the supersensitive behavioral responses induced by L-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine. J. Pharmacol. Exp. Ther. 235:1985;287-295.
5. Breese G.R., Criswell H.E., Duncan G.E., Mueller R.A. A dopamine deficiency model of Lesch-Nyhan disease - The neonatal-6-OHDA-lesioned rat. Brain Res. Bull. 25:1990;477-484.
6. Criswell H., Mueller R.A., Breese G.R. Priming of D1-dopamine receptor responses. Long-lasting behavioral supersensitivity to a D1-dopamine agonist following repeated administration to naonatal 6-OHDA-lesioned rats J. Neurosci. 9:1989;125-133.
7. Cunningham S.T., Finn M., Kelley A.E. Sensitization of the locomotor response to psychostimulants after repeated opiate exposure. Role of the nucleus accumbens Neuropsychopharmacology. 16:1997;147-155.
8. Frohna P.A., Neal-Beliveau B.S., Joyce J.N. Delayed plasticity of the mesolimbic dopamine system following neonatal 6-OHDA lesions. Synapse. 25:1997;293-305.
9. Gainetdinov R.R., Wetsel W.C., Jones S.R., Levin E.D., Jaber M., Caron M.G. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science. 283:1999;397-401.
10. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 379:1996;601-612.
11. Graybiel A.M., Moratalla R., Robertson H.A. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc. Natl. Acad. Sci. USA. 87:1990;6912-6916.
12. Kalivas P.W., Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res. Rev. 16:1991;223-244.
13. Karler R., Chaudhry I.A., Calder L.D., Turkanis S.A. Amphetamine behavioral sensitization and the excitatory amino acids. Brain Res. 537:1990;76-82.
14. Karler R., Calder L.D., Thai L.H., Bedingfield J.B. A dopaminergic-glutamatergic basis for the action of amphetamine and cocaine. Brain Res. 658:1994;8-14.
15. Kars H., Broekema W., Glaudemans-van Gelderen I., Verhoeven W.M., van Ree J.M. Naltrexone attenuates self-injurious behavior in mentally retarded subjects. Biol. Psychiatry. 27:1990;741-746.
16. Konradi C., Leveque J.C., Hyman S.E. Amphetamine and dopamine-induced immediate early gene expression in striatal neurons depends on postsynaptic NMDA receptors and calcium. J. Neurosci. 16:1996;4231-4239.
17. Lloyd K.G., Hornykiewicz O., Davidson L., Shannak K., Farley I., Goldstein M., Shibuya M., Kelley W.N., Fox I.H. Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. N. Engl. J. Med. 305:1981;1106-1111.
18. Minana M.D., Portoles M., Jorda A., Grisolia S. Lesch-Nyhan syndrome, caffeine model. Increase of purine and pyrimidine enzymes in rat brain J. Neurochem. 43:1984;1556-1560.
19. Mizuno T.-I., Yugari Y. Self-mutilation in Lesch-Nyhan syndrome. Lancet. 1:1974;761.
20. Mizuno T.-I., Yugari Y. Prophylactic effect of L-5HTP on self-mutilation in the Lesch-Nyhan syndrome. Neuropadiatrie. 6:1975;13-23.
21. Mueller K., Nyhan W.L. Pharmacologic control of pemoline induced self-injurious behavior in rats. Pharmcol. Biochem. Behav. 16:1982;957-963.
22. Mueller K., Saboda S., Palmour R., Nyhan W.L. Self-injurious behavior in rats by daily caffeine and continuous amphetamine. Pharmacol. Biochem. Behav. 17:1982;613-617.
23. Richardson J.S., Zaleski W.A. Naloxone and self-mutilation. Biol. Psychiatry. 18:1983;99-101.
24. Sandman C.A., Barron J.L., Colman H. An orally administered opiate blocker, naltrexone, attenuates self-injurious behavior. Am. J. Ment. Retard. 95:1990;93-102.
25. Seiden L.S., Sabol K.E., Ricaurte G.A. Amphetamine. Effects on catecholamine systems and behavior Annu. Rev. Pharmacol. Toxicol. 32:1993;639-677.
26. Snyder-Keller A.M. Striatal c-fos induction by drugs and stress in neonatally dopamine-depleted rats given nigral transplants. Importance of NMDA activation and relevance to sensitization phenomena Exp. Neurol. 113:1991;155-165.
27. Stewart J., Druhan J.P. Developmental of both conditioning and sensitization of the behavioral activating effects of amphetamine is blocked by the non-competitive NMDA receptor antagonist, MK-801. Psychopharmacology (Berlin). 110:1993;125-132.
28. Thomas W.S., Neal-Beliveau B.S., Joyce J.N. There is a limited critical period for dopamine's effects on D1 receptor expression in the developing rat neostriatum. Dev. Brain Res. 111:1998;99-106.
29. Weld K.P., Mench J.A., Woodward R.A., Bolesta M.S., Suomi S.J., Higley J.D. Effect of tryptophan treatment on self-biting and central nervous system serotonin metabolism in rhesus monkeys (Macaca mulatta). Neuropsychopharmacology. 19:1998;314-321.
30. Wilson J.M., Young A.B., Kelley W.N. Hypoxanthine-guanine phosphoribosyltransferase deficiency. N. Engl. J. Med. 309:1983;900-910.
31. Winchel R.M., Stanley M.S. Self-injurious behavior. A review of the behavior and biology of self-mutilation Am. J. Psychiatry. 148:1991;306-317.
32. Wong D.F., Harris J.C., Naidu S., Yokoi F., Marenco S., Dannals R.F., Ravert H.T., Yaster M., Evans A., Rousset O., Bryan R.N., Gjedde A., Kuhar M.J., Breese G.R. Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc. Natl. Acad. Sci. USA. 93:1996;5539-5543.
33. Zaczek R., Battaglia G., Contrera J.F., Culp S., De Souza E.B. Methylphenidate and pemoline do not cause depletion of rat brain monoamine markers similar to that observed with methamphetamine. Toxicol. Appl. Pharmacol. 100:1989;227-233.
34. Zurita A., Murua S., Molina V. An endogenous opiate mechanism seems to be involved in stress-induced anhedonia. Eur. J. Pharmacol. 299:1996;1-7.